Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice.

[1]  G. Newton,et al.  Acute Effects of β1-Selective and Nonselective β-Adrenergic Receptor Blockade on Cardiac Sympathetic Activity in Congestive Heart Failure , 1996 .

[2]  B. Johansson.  Effect of beta blockade on ventricular fibrillation- and ventricular tachycardia-induced circulatory arrest in acute myocardial infarction. , 1986, The American journal of cardiology.

[3]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[4]  T. Levine,et al.  Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. , 1994, Circulation.

[5]  A. Lenarda,et al.  Acute hemodynamic effects of carvedilol versus metoprolol in idiopathic dilated cardiomyopathy , 1991 .

[6]  U. Ikeda,et al.  Alpha 1-adrenergic stimulation is coupled to cardiac myocyte hypertrophy. , 1991, The American journal of physiology.

[7]  K Caidahl,et al.  Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. , 1989, Circulation.

[8]  J. A. Bowers,et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. , 1996, Circulation.

[9]  G. Sinagra,et al.  Effects of carvedilol on LV function and remodeling in patients with dilated cardiomyopathy with persistent LV dysfunction despite optimal conventional therapy , 1998 .

[10]  J. Reid,et al.  Epinephrine-induced hypokalemia: the role of beta adrenoceptors. , 1986, The American journal of cardiology.

[11]  R. Doughty,et al.  Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. , 1997, European heart journal.

[12]  S. Umemura,et al.  Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin. , 1985, Circulation research.

[13]  E. Braunwald,et al.  Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. , 1963, The American journal of medicine.

[14]  D. Renlund,et al.  Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. , 1990, The American journal of medicine.

[15]  G. Plotnick,et al.  Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. , 1994, Journal of the American College of Cardiology.

[16]  K. Chien,et al.  The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. , 1993, The Journal of biological chemistry.

[17]  P. Palatini,et al.  ORTHOSTATIC HYPOTENSION AFTER THE FIRST ADMINISTRATION OF PRAZOSIN IN HYPERTENSIVE PATIENTS: ROLE OF THE PLASMA VOLUME , 1981, Clinical and experimental pharmacology & physiology.

[18]  R. Gorlin,et al.  Hemodynamic and Clinical Tachyphylaxisc to Prazosin-Mediated Afterload Reductionin Severe Chronic Congestive Heart Failure , 1979, Circulation.

[19]  P. Grayburn,et al.  Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. , 1994, Journal of the American College of Cardiology.

[20]  N. Alpert,et al.  Altered Myocardial Force‐Frequency Relation in Human Heart Failure , 1992, Circulation.

[21]  M. Simons,et al.  Coronary vasoconstriction and catecholamine cardiomyopathy. , 1985, American heart journal.

[22]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[23]  J. Cohn,et al.  Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. , 1994, Journal of the American College of Cardiology.

[24]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[25]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[26]  E. Braunwald,et al.  The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. , 1966, Annals of internal medicine.

[27]  W. French,et al.  Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. , 1994, Circulation.

[28]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[29]  R. Hershberger,et al.  Alpha-1 adrenergic receptors in the nonfailing and failing human heart. , 1988, The Journal of pharmacology and experimental therapeutics.

[30]  G. Bonardi,et al.  Renal function studies with cadralazine in conscious dogs: a comparison with hydralazine. , 1989, Pharmacological research.

[31]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[32]  J. Anderson,et al.  A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. , 1985, The American journal of cardiology.

[33]  E. Johns,et al.  The role of α‐adrenoceptors in the regulation of renal tubular sodium reabsorption and renin secretion in the rabbit , 1985, British journal of pharmacology.

[34]  D. Renlund,et al.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. , 1991, Circulation.

[35]  P. Armstrong,et al.  α1-Adrenoceptor activity in arterial smooth muscle following congestive heart failure , 1989 .

[36]  M. Packer.  End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? , 1997, The New England journal of medicine.

[37]  L. Krusell,et al.  Proximal renal tubular pressure-natriuresis-relation in essential hypertensives following acute vasodilatation. , 1993, Blood pressure.

[38]  M. Packer,et al.  Pathophysiology of chronic heart failure , 1992, The Lancet.

[39]  M. Packer.  How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. , 1993, The American journal of cardiology.

[40]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[41]  G Olivetti,et al.  Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. , 1986, Journal of the American College of Cardiology.

[42]  M. Bristow,et al.  Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. , 1995, European heart journal.

[43]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[44]  Milton Packer,et al.  Safety and efficacy of carvedilol in severe heart failure , 1997 .

[45]  M. Metra,et al.  Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. , 1994, Journal of the American College of Cardiology.

[46]  M. Borgers,et al.  Nebivolol Increases Survival in Cardiomyopathic Hamsters with Congestive Heart Failure , 1991, Journal of cardiovascular pharmacology.

[47]  H. Krum,et al.  Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. , 1995, Circulation.

[48]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[49]  C. Bahr,et al.  α‐Receptor function changes after the first dose of prazosin , 1982, Clinical pharmacology and therapeutics.

[50]  P. Chatelain,et al.  Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heart , 1995, British journal of pharmacology.

[51]  M. Bristow,et al.  Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. , 1996, Circulation.

[52]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[53]  M. Hori,et al.  Role of increased alpha 1-adrenergic activity in cardiomyopathic Syrian hamster. , 1991, The American journal of physiology.

[54]  DiBona Gf.  Neural control of renal function: role of renal alpha adrenoceptors. , 1985 .

[55]  G. Billman,et al.  Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. , 1997, Circulation.

[56]  P. Heidenreich,et al.  Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. , 1997, Journal of the American College of Cardiology.

[57]  L. Opie,et al.  Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. , 1992, Journal of the American College of Cardiology.

[58]  B. Parsons,et al.  Adrenergic Effects on the Biology of the Adult Mammalian Cardiocyte , 1992, Circulation.

[59]  H. Schelbert,et al.  Evidence for preserved cardiopulmonary baroreflex control of renal cortical blood flow in humans with advanced heart failure. A positron emission tomography study. , 1995, Circulation.

[60]  S. Gottlieb,et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. , 1996, Circulation.

[61]  F. Waagstein,et al.  Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. , 1994, Journal of the American College of Cardiology.

[62]  R. Gunnar,et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. , 1985, Circulation.

[63]  A. Kanai,et al.  β-Adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. , 1997, American journal of physiology. Cell physiology.

[64]  S. G. Pollock,et al.  Usefulness of bucindolol in congestive heart failure. , 1990, The American journal of cardiology.

[65]  M. Rosen,et al.  An alpha-1-adrenergic receptor subtype is responsible for delayed afterdepolarizations and triggered activity during simulated ischemia and reperfusion of isolated canine Purkinje fibers. , 1991, Circulation.

[66]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[67]  R. Byington,et al.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.

[68]  J. A. Thomas,et al.  Plasma norepinephrine in congestive heart failure. , 1978, The American journal of cardiology.

[69]  S. Downing,et al.  Contribution of γ‐Adrenoceptor Activation to the Pathogenesis of Norepinephrine Cardiomyopathy , 1983, Circulation research.

[70]  D. Renlund,et al.  Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. , 1995, Journal of the American College of Cardiology.

[71]  H. Zimmer,et al.  Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. , 1989, Circulation research.